|
Subscribe to The Burrill Report | Don't forget to join us on  Facebook or  Twitter
Returning to Growth
Podcast: July 1, 2013
Worldwide prescription drug sales in dollar terms fell for the first time in 2012, a result of competition from generic drugs, price controls, and austerity measures in the Eurozone. But Evaluate Pharma sees a return to modest growth in 2013 and some encouraging signs for the outlook for the industry longer term. We spoke to Jonathan de Pass, CEO of Evaluate Group, about the company’s newly released World Preview report, the growing importance of biologics as a driver of growth for the pharmaceutical industry, and why both the quantity and quality of newly approved drugs should provide encouragement to investors. Read More Here
By The Numbers
|
Biggest movers for the week ending June 28, 2013
|
| TICKER |
COMPANY |
CLOSING PRICE 6/14/2013 |
CLOSING PRICE 6/21/2013
|
PRICE CHANGE |
PERCENT CHANGE |
|
| ADVANCERS |
| KIOR |
Kior |
4.10 |
5.67 |
1.57 |
38.3% |
| HALO |
Halozyme Therapeutics |
6.15 |
7.99 |
1.84 |
29.8% |
| BSE:533288 |
Claris Lifesciences |
164.6 |
204.1 |
39.50 |
24.0% |
| GERN |
Geron |
1.21 |
1.50 |
0.29 |
24.0% |
| INSY |
Insys Therapeutics |
11.21 |
13.79 |
2.58 |
23.0% |
| DECLINERS |
| TSX:RVX |
Resverlogix |
2.21 |
0.23 |
-1.99 |
-89.8% |
| QLTI |
QLT |
8.33 |
4.40 |
-3.93 |
-47.2% |
| TSE:4587 |
PeptiDream |
11200 |
7190 |
-4010 |
-35.8% |
| TSE:4583 |
Chiome Bioscience |
5175 |
3830 |
-1345 |
-26.0% |
| JASDAQ:7777 |
3-D Matrix |
5490 |
4180 |
-1310 |
-23.9% |
| Includes life sciences stocks with closing price of $1 or more on June 21, 2013, |
Resverlogix Tanks on News of Failed Atherosclerosis Drug Trial
Markets and indices moved up in hopes that the weak economic and employment numbers would keep the Fed from easing economic supports. For the week, The Dow Jones Industrial Average was up 0.7 percent, the S&P 500 rose 0.9 percent, and the Nasdaq Composite Index was up 1.4 percent. Biotech led the index advancers with the NYSE biotech index up 5 percent and the Burrill Select index up 5.2 percent.
KiOR rose 38.3 percent after its presentation at the Global Hunter Securities GHS 100 Energy Conference in Chicago. On Thursday June 27 more than 1.2 million shares traded in one day, the largest number since November 2012.
Resverlogix dropped almost 90 percent due to a failed mid-stage trial evaluating its lead candidate drug for the treatment or stabilization of atherosclerosis. The drug is a new class of potential therapeutics that increases production of proteins, in this case the beneficial Apo1, by removing the block created by inhibitory regulators of gene transcription. The company will analyze the full data set over the next months to determine if continued development of the compound is warranted for other indications in cardiovascular disease.
Prosensa IPO Hits the Market Running
Offering tops busy week with four life sciences issues debuting on the Nasdaq.
The Dutch biotech Prosensa completed an upsized initial public offering in the United States, raising $78 million. The offering capped a week when four life sciences companies completed IPOs, putting an exclamation point at the end of the year’s first half. Read More Here
| BURRILL INDICES |
12/31/2012 |
6/21/2013 |
6/28/2013 |
Week Change |
Year Change |
| Burrill Select |
589.98 |
750.45 |
789.39 |
5.2% |
33.8% |
| Burrill Large Cap |
736.90 |
896.16 |
939.48 |
4.8% |
27.5% |
| Burrill Mid-Cap |
309.52 |
372.41 |
386.75 |
3.9% |
25.0% |
| Burrill Small Cap |
105.48 |
125.59 |
132.07 |
5.2% |
25.2% |
| Burrill Diagnostics |
191.32 |
203.49 |
207.09 |
1.8% |
8.2% |
| Burrill Personalized Medicine |
119.22 |
141.89 |
147.30 |
3.8% |
23.5% |
| Burrill Biogreentech |
162.27 |
172.70 |
175.61 |
1.7% |
8.2% |
| NASDAQ |
3019.51 |
3357.25 |
3403.25 |
1.4% |
12.7% |
| DJIA |
13104.14 |
14799.40 |
14909.60 |
0.7% |
13.8% |
| S&P 500 |
1426.19 |
1592.43 |
1606.28 |
0.9% |
12.6% |
| Amex Biotech |
1547.03 |
1862.72 |
1956.26 |
5.0% |
26.5% |
| Amex Pharmaceutical |
369.57 |
413.5 |
413.90 |
0.1% |
12.0% |
| NASDAQ Biotechnology Index |
1430.81 |
1758.53 |
1813.15 |
3.1% |
26.7% |
Roche and AstraZeneca to Share Early-Stage Data
Consortium is latest effort among pharmaceutical companies to cut development costs through cooperation.
Roche and AstraZeneca said they have formed a collaboration to share early-stage drug design data in the hopes of accelerating drug development and improving their success rates. Read More Here
SCOTUS Decision Limits Liability for Generic Drugmakers
Court in 5-4 decision says these companies can’t be held responsible for design defects.
The U.S. Supreme Court ruled that design defect claims against generic drugmakers cannot be brought under state laws because federal law preempts them, a ruling that insulates manufacturers from liability when people who use their drugs are harmed by them. Read More Here
Sandoz Advances Enbrel Biosimilar
Drug company lays the groundwork for seeking approval from U.S. and E.U. regulators.
Sandoz has launched a late-stage trial of a biosimilar version of etanercept, the blockbuster psoriasis and rheumatoid arthritis therapy marketed as Enbrel. Read More Here
Viehbacher Threatens to Cut Sanofi R&D Spending in Europe
CEO says pessure to open trials data and lower drug prices will push drugmakers to seek more business-friendly environments.
Sanofi CEO Chris Viehbacher says that pressure by European regulators to release detailed clinical trials data on innovative therapies may drive his company to direct investments elsewhere. Read More Here
Astellas Provides New Muscle to Cytokinetics with Collaboration
Deal worth up to $490 million.
Cytokinetics and Astellas Pharma signed a two-year collaboration that will bring more than $40 million in upfront payments and research funding to Cytokinetics during the first two years of the agreement. Read More Here
Monsanto Taps Nimbus Discovery in Crop Protection Pact
Companies will collaborate to develop novel fungicides.
Monsanto and Nimbus Discovery will collaborate to develop broad-spectrum fungicides with new modes of action to help farmers control plant diseases. Fungal infections, which appear as rusts, leaf spots, and blights on a range of important food crops, are estimated to result in significant global crop losses each year. Read More Here
Decision Misprision
SCOTUS ruling a set back to addressing quality concerns in generic drugs.
http://www.burrillreport.com/article-decision_misprision.html It seems that lately, when it comes to healthcare policy, we are living in the land of unintended consequences. Read More Here
Resverlogix Tanks Following Failure of Lead Drug
The weekly round-up of failed trials, missed targets, and other business mishaps.
Resverlogix’ shares fell 90 percent after it said its lead experimental drug for the treatment or stabilization of atherosclerosis failed a mid-stage trial in patients with cardiovascular disease that had reduced high-density lipoprotein levels. Read More Here
|
Print
.gif)
